BERLIN (Reuters) – The German cartel office has approved a deal by Denmark’s Novo Nordisk to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
The acquisition of Hanover-based Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) comes as Novo works to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.
(Writing by Rachel More; Editing by Miranda Murray)
